Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY EBITDA Margin

EBITDA as a percentage of revenue.

Incyte CorporationNASDAQ: INCY

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 46.5%

EBITDA Margin was 46.5% in Q2 FY2026, down 1.3 pp from a year earlier. On a trailing-twelve-month basis it was 35.5%, up 6.0 pp year over year. Over 3 fiscal years it widened by 16.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 17 analysts of 19.7% for the fiscal year ending Dec 2026, down from 34.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
46.5%+17.6 pp QoQ
Last fiscal yearDec 2025
34.2%+24.6 pp YoY
LTMJun 2026
35.5%+6.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.3 pp-89.8 pp-88.5 pp
1 year+24.6 pp-14.6 pp-39.2 pp
3 years+16.6 pp+13.5 pp-3.1 pp
5 years-7.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
34.2%
Year-over-year change
+24.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 EBITDA Margin of 35.5% is the 5th highest of the 8 companies compared; the peer median is 37.0%.
  • Its year-over-year change of +6.0 pp is the 6th highest of 7, against a peer median of +73.2 pp.
  • Over three fiscal years its change of +16.6 pp compares with a peer median of +30.5 pp.
INCY Competitors Peer median
EBITDA Margin for INCY and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202694.3% +118.8 pp+30.5 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202637.0% -1.1 pp-2.6 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
VSTMVerastem, Inc.LTM Mar 2026-387.1% +1063.3 pp+2084.9 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding INCY) 37.0%+73.2 pp+30.5 pp

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.